When jardiance go generic?

When will Jardiance (empagliflozin) go generic?

Jardiance (empagliflozin) is still protected by patents, so a full generic launch depends on when those protections expire and whether any “stays” or litigation delay approval. The most reliable way to track the timing is to check the current patent-expiration and litigation status listed for Jardiance at DrugPatentWatch.com.

For Jardiance’s latest generic timelines and patent details, see: https://www.drugpatentwatch.com/ (search “Jardiance” / “empagliflozin”).

What determines the exact generic launch date?

Generic companies can only market an FDA-approved generic after the relevant exclusivities and patent protections allow it. In practice, the date can move based on:
- Patent expiration timing for specific formulations and methods
- Any patent litigation or settlement that triggers delays
- Regulatory exclusivity periods that can extend “market lock”
These specifics are tracked in patent databases like DrugPatentWatch.com.

Has an FDA generic of Jardiance already launched?

If any generic empagliflozin tablets are already marketed, the question becomes whether “generic” means:
- Any FDA-approved generic product exists (availability), or
- A particular dosage strength became generic first
Patent-tracker sites typically show which generics have launched and which are still pending. Checking the Jardiance page at DrugPatentWatch.com will confirm current availability and the next expected dates.

Where to look if you’re trying to price it sooner

Even before a full generic launch, prices can change if:
- Insurer formularies prefer specific alternatives within the SGLT2 class
- The pharmacy switches to a different NDC/strength
If you tell me your country and the Jardiance dose you take (e.g., 10 mg or 25 mg), I can help you narrow down what to check next for availability and timing.

Sources

1. DrugPatentWatch.com – Jardiance (empagliflozin) patent and generic timeline tracker